GSK Bio
NEWS
In the October 2 verdict, Circuit Judge Pauline Newman said that promotional materials, press releases, product catalogs, FDA labels and witness testimony did support the “induced infringement” judgement against Teva.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The new approval makes it the first FDA-approved therapy in over a decade to treat HES and the third indication for the therapy overall.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.
GlaxoSmithKline’s Trelegy Ellipta won regulatory approval for the treatment of asthma in patients aged 18 years and older. Here’s what you need to learn.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.
Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.
JOBS
IN THE PRESS